IP Library › Granted Patent US 12,383,600
Granted Patent B2
US 12,383,600 · App. 18/052,768 · Granted Aug 12, 2025

C3B binding polypeptide

Inventors: Paul Bishop (London, GB); Simon Clark (London, GB); Richard Unwin (London, GB)
Assignee: Complement Therapeutics Limited
A61K38/1709A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,600
App. No.
18/052,768
Granted
Aug 12, 2025
Kind
B2
Abstract

Polypeptides comprising a C3b binding region are disclosed, as well as nucleic acids and vectors encoding such polypeptides, and cells and compositions comprising such polypeptides. Also disclosed are uses and methods using the polypeptides for treating and preventing diseases and conditions.

Claims (20)

1. A method for inhibiting complement activation in a subject, the method comprising administering or expressing a polypeptide which is capable of binding to C3b, the polypeptide comprising an amino acid sequence wherein said amino acid sequence consists of a sequence having at least 90% identity to SEQ ID NO:2, wherein the amino acid at position 111 of SEQ ID NO:2 is A, the amino acid at position 157 of SEQ ID NO:2 is P, and the amino acid at position 160 of SEQ ID NO:2 is G, and wherein the polypeptide has a total length of 450 amino acids or fewer.

2. The method according to claim 1 , wherein the subject has a disease associated with complement dysregulation or overactivation, wherein the disease is not an ocular disease.

3. The method according to claim 1 , wherein the subject has a kidney disease or condition.

4. The method according to claim 1 , wherein the subject has atypical Haemolytic Uremic Syndrome (aHUS), Membranoproliferative Glomerulonephritis Type II (MPGN II), sepsis, or Paroxysmal nocturnal hemoglobinuria (PNH).

5. The method according to claim 1 , wherein the polypeptide has a total length of 250 amino acids or fewer.

6. The method according to claim 1 , wherein the method comprises administering a nucleic acid encoding the polypeptide.

7. The method according to claim 6 , wherein the nucleic acid comprises a sequence having at least 85% sequence identity to SEQ ID NO:35.

8. The method according to claim 1 , wherein the method comprises modifying at least one cell of a subject to express or comprise a nucleic acid encoding the polypeptide.

9. The method according to claim 8 , wherein the nucleic acid comprises a sequence having at least 85% sequence identity to SEQ ID NO:35.

10. The method according to claim 1 , wherein the method comprises administering a vector comprising a nucleic acid encoding the polypeptide to at least one cell of a subject.

11. The method according to claim 10 , wherein the nucleic acid comprises a sequence having at least 85% sequence identity to SEQ ID NO:35.

12. The method according to claim 10 , wherein the vector is a viral vector.

13. A method according to claim 10 , wherein the vector is a lentiviral vector, a retroviral vector, a gammaretroviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, a vaccinia virus vector, or a herpesvirus vector.

14. A method according to claim 10 , wherein the vector is an adeno-associated viral (AAV) vector comprising a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11, or hybrids and/or mutants thereof.

15. The method according to claim 1 , wherein the polypeptide or amino acid sequence comprises or consists of SEQ ID NO:2 or SEQ ID NO:3.

16. The method according to claim 1 , wherein the polypeptide or amino acid sequence comprises a secretory pathway sequence comprising, or consisting of, SEQ ID NO: 7.

17. The method according to claim 16 , wherein the polypeptide or amino acid sequence comprises, or consists of, a sequence having at least 95% sequence identity to SEQ ID NO:47 or 49.

18. The method according to claim 16 , wherein the polypeptide or amino acid sequence comprises a cleavage site for removing the secretory pathway sequence.

19. The method according to claim 1 , wherein the method comprises simultaneous or sequential administration or expression of Complement Factor I.

20. The method according to claim 1 , wherein the method comprises simultaneous or sequential administration or expression of a nucleic acid encoding Complement Factor I.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2024
From: THE UNIVERSTY OF MANCHESTER
To: COMPLEMENT THERAPEUTICS LIMITED
Reel/Frame 066594/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2024
From: BISHOP, PAUL; CLARK, SIMON; UNWIN, RICHARD
To: THE UNIVERSITY OF MANCHESTER
Reel/Frame 066702/0686 →
Priority Claims (1)
GB 1800620 · Jan 15, 2018 · national
Continuity (2)
Continuation 16962108
Related Publication 20230310545A1 · Oct 5, 2023
References Cited (108)
US 5679546A · Ko et al. · 1997 [cited by applicant]
US 5981481A · Fearon et al. · 1999 [cited by applicant]
US 6458360B1 · Fearon et al. · 2002 [cited by applicant]
US 6551595B1 · Rosengard et al. · 2003 [cited by applicant]
US 8664176B2 · Marsh et al. · 2014 [cited by applicant]
US 11524050B2 · Bishop et al. · 2022 [cited by applicant]
US 20030049831A1 · Murphy · 2003 [cited by applicant]
US 20030086940A1 · Costa et al. · 2003 [cited by applicant]
US 20040146938A1 · Nguyen et al. · 2004 [cited by applicant]
US 20050112139A1 · Karp · 2005 [cited by applicant]
US 20050169921A1 · Bell et al. · 2005 [cited by applicant]
US 20050222027A1 · Chiang et al. · 2005 [cited by applicant]
US 20050277158A1 · Chen · 2005 [cited by applicant]
US 20060140939A1 · Fung · 2006 [cited by applicant]
US 20070065433A1 · Mollnes et al. · 2007 [cited by applicant]
US 20070093443A1 · Madison et al. · 2007 [cited by applicant]
US 20070274989A1 · Fung et al. · 2007 [cited by applicant]
US 20080075728A1 · Newman · 2008 [cited by applicant]
US 20080118506A1 · An et al. · 2008 [cited by applicant]
US 20080193414A1 · Proudfoot et al. · 2008 [cited by applicant]
US 20080221011A1 · Gilkeson et al. · 2008 [cited by applicant]
US 20090214538A1 · Fung et al. · 2009 [cited by applicant]
US 20090269338A1 · Huang et al. · 2009 [cited by applicant]
US 20090324585A1 · Robinson et al. · 2009 [cited by applicant]
US 20100009393A1 · Morgan et al. · 2010 [cited by applicant]
US 20100130413A1 · Marsh et al. · 2010 [cited by applicant]
US 20100240075A1 · Granoff et al. · 2010 [cited by applicant]
US 20110091450A1 · Schwaeble et al. · 2011 [cited by applicant]
US 20110190221A1 · Francois et al. · 2011 [cited by applicant]
US 20110229497A1 · Thurman et al. · 2011 [cited by applicant]
US 20120107315A1 · Behrens et al. · 2012 [cited by applicant]
US 20120225056A1 · Rother et al. · 2012 [cited by applicant]
US 20120258095A1 · Demopulos et al. · 2012 [cited by applicant]
US 20130029912A1 · Holers et al. · 2013 [cited by applicant]
US 20130064820A1 · Magro · 2013 [cited by applicant]
US 20130078245A1 · Holers et al. · 2013 [cited by applicant]
US 20130190477A1 · Kovacs et al. · 2013 [cited by applicant]
US 20130217616A1 · Garred et al. · 2013 [cited by applicant]
US 20130225795A1 · Schmidt et al. · 2013 [cited by applicant]
US 20150079084A1 · Her et al. · 2015 [cited by applicant]
US 20150247143A1 · Fitzgerald et al. · 2015 [cited by applicant]
US 20160083469A1 · Rohrer et al. · 2016 [cited by applicant]
US 20160237125A1 · Barlow et al. · 2016 [cited by applicant]
US 20160311893A1 · Patz, Jr. et al. · 2016 [cited by applicant]
US 20160326231A1 · Hu et al. · 2016 [cited by applicant]
US 20170190753A1 · Abache · 2017 [cited by applicant]
US 20200277360A1 · Clark et al. · 2020 [cited by applicant]
EP 0222611A2 · 1987 [cited by applicant]
EP 2083841B1 · 2013 [cited by applicant]
WO WO198909220A1 · 1989 [cited by applicant]
WO WO199210205A1 · 1992 [cited by applicant]
WO WO199400571A1 · 1994 [cited by applicant]
WO WO199416719A1 · 1994 [cited by applicant]
WO WO1995008570A1 · 1995 [cited by applicant]
WO 199509239A2 · 1995 [cited by applicant]
WO WO199509239A3 · 1995 [cited by applicant]
WO WO199944625A1 · 1999 [cited by applicant]
WO WO200061752A2 · 2000 [cited by applicant]
WO WO2007149567A2 · 2007 [cited by applicant]
WO 2008048675A2 · 2008 [cited by applicant]
WO WO2008048675A3 · 2008 [cited by applicant]
WO WO2008154251A2 · 2008 [cited by applicant]
WO WO2009056631A2 · 2009 [cited by applicant]
WO WO2010056399A1 · 2010 [cited by applicant]
WO WO2011057158A1 · 2011 [cited by applicant]
WO WO2011163412A1 · 2011 [cited by applicant]
WO WO2012037370A1 · 2012 [cited by applicant]
WO WO2012095519A1 · 2012 [cited by applicant]
WO WO2013082563A1 · 2013 [cited by applicant]
WO 2013151665A2 · 2013 [cited by applicant]
WO WO2012095519 · 2014 [cited by applicant]
WO WO2015023972A1 · 2015 [cited by applicant]
WO WO2016022914A1 · 2016 [cited by applicant]
WO WO2016028150A1 · 2016 [cited by applicant]
WO WO2017053732A2 · 2017 [cited by examiner]
WO WO2017053732A3 · 2017 [cited by applicant]
WO WO2017194912A1 · 2017 [cited by applicant]
WO WO2018002131A1 · 2018 [cited by examiner]
WO WO2018224663A1 · 2018 [cited by applicant]
WO PCTEP2019050949 · 2019 [cited by applicant]
WO WO2019138137A1 · 2019 [cited by applicant]
U.S. Appl. No. 16/962,108, filed Jul. 14, 2020, Paul Bishop et al. [cited by applicant]
U.S. Appl. No. 18/048,303, filed Oct. 20, 2022, Paul Bishop et al. [cited by applicant]
Akkerman et al (Blood, Nov. 12, 2009, vol. 114, No. 20, 4323-4324) (Year: 2009). [cited by applicant]
Clark et al. “Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula and Relevance to Age-Related Macular Degeneration.” J Clin Med. 4(1): 18-31 (2015). [cited by applicant]
Clark et al., Bruch's Membrane Compartmentalizes Complement Regulation in the Eye with Implication for Therapeutic Design in Age-Related Macular Degeneration, Original Research, 2017, vol. 8, pp. 1-10. [cited by applicant]
Clark et al., Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implication forge-related denegeration, J. Immunol., 2014, vol. 193(10), pp. 4962-4970. [cited by applicant]
Clark et al., Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Brunch's membrane in human retina, The Journal of Biological Chemistry, 2010, vol. 285(39), pp. 3019… [cited by applicant]
Fenaille et al. “Site-specific N-glycan characterization of human complement factor H.” Glycobiology 17(9): 932-944 (2007). [cited by applicant]
Foley et al. “Interplay between fibrinolysis and complement: plasmin cleavage of iC3B modulates immune responses.” Journal of Thrombosis and Haemostasis 13(4): 610-618 (2014). [cited by applicant]
Forest et al., Cellular models and therapies for age-related macular degeneration, Disease Models and Mechanisms, 2015, vol. 8, pp. 421-427. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2018/065199 dated Oct. 19, 2018, 17 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2019/050949 dated Sep. 10, 2018, 12 pages. [cited by applicant]
Kirkitadze et al., Independently Melting Modules and Highly Structured Intermodular Junctions within Complement Receptor Type 1, Biochemistry, 1999, vol. 38(2), pp. 7019-7031. [cited by applicant]
Mathern et al. “Molecules great and small: the complement system.” Clinical Journal of the American Society of Nephrology 10(9): 1636-1650 (2015). [cited by applicant]
Thomas. “Furin at the cutting edge: from protein traffic to embryogenesis and disease.” Nature reviews Molecular cell biology 3(10): 753-766 (2002). [cited by applicant]
Tsiftsoglou et al. “Human complement factor I does not require cofactors for cleavage of synthetic substrates.” The Journal of Immunology 173(1): 367-375 (2004). [cited by applicant]
UK Search Report GB 1800620.5 dated Oct. 17, 2018, 2 pages. [cited by applicant]
Wang. “Association between complement factor I gene polymorphisms and the risk of age-related macular degeneration: a Meta-analysis of literature.” International Journal of Ophthalmology 9(2): 298-305 (2016). [cited by applicant]
Whitmore et al., Complement activation and chroiocapillaris loss in early AMD: Implication for pathophysiology and therapy, 2015, Prog. Retin Eye Res., pp. 1-71. [cited by applicant]
Wu et al. “Structure of complement fragment C3b-factor H and implications for host protection by complement regulators” Nature immunology 10(7): 728-733 (2009). [cited by applicant]
Zhang et al., Soluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy, J Am Sco Nephrol, 2013, vol. 24, pp. 1820-1829. [cited by applicant]
Zipfel et al. “The Role of Complement in AMD.” In: Lambris J., Adamis A. (eds) Inflammation and Retinal Disease: Complement Biology and Pathology. Advances in Experimental Medicine and Biology, vol. 703. Springer, New Y… [cited by applicant]
Zipfel et al., The Role of Complement in AMD, 2010. Adv Excp Med Bio., vol. 285(39), pp. 30192-30202. [cited by applicant]
Fernandez-Godino et al., “Changes in extracellular matrix cause RPE cells to make basal deposits and activate the alternative complement pathway,” Hum Mol Genet. 2018 27(1):147-159. [cited by applicant]
Rathi et al., “Therapeutic targeting of the complement system in ocular disease,” 2023 Drug Discovery Today 28(11) 1-21. [cited by applicant]
Hourcade et al., Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem. Jan. 11, 2002;277(2):1107… [cited by applicant]
Extended European Search Report for Application No. EP 24213690.1, mailed Mar. 28, 2025. [cited by applicant]
Cited By (1)
US 12,544,423